

ACADIA PHARMACEUTICALS INC  
Form 8-K  
June 19, 2006

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 06/13/2006**

**ACADIA Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter)

**Commission File Number: 000-50768**

**Delaware**  
(State or other jurisdiction of  
incorporation)

**06-1376651**  
(IRS Employer  
Identification No.)

**3911 Sorrento Valley Boulevard**  
San Diego, CA 92121  
(Address of principal executive offices, including zip code)

**(858) 558-2871**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 8-K

Information to be included in the report

**Item 1.01. Entry into a Material Definitive Agreement**

On June 13, 2006, our Board of Directors created a new Scientific Advisory Committee of the board and approved an updated compensation program for outside directors (i.e. non-employees) to reflect changes for this new committee. The description of the outside director compensation plan is set forth in Exhibit 99.1 hereto.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

Exhibit Number	Description
99.1	Outside Director Compensation Plan.

---

**Signature(s)**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA Pharmaceuticals Inc.

Date: June 19, 2006

By: /s/ Glenn F. Baity

---

Glenn F. Baity  
General Counsel & Assistant Secretary

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	Outside Director Compensation Plan